These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1674 related articles for article (PubMed ID: 17635819)

  • 21. The role of bone in phosphate metabolism.
    Fukumoto S
    Mol Cell Endocrinol; 2009 Oct; 310(1-2):63-70. PubMed ID: 18822343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting.
    Bacchetta J; Bardet C; Prié D
    Metabolism; 2020 Feb; 103S():153865. PubMed ID: 30664852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.
    Quarles LD
    Exp Cell Res; 2012 May; 318(9):1040-8. PubMed ID: 22421513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF23 and disorders of phosphate homeostasis.
    Yu X; White KE
    Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of fibroblast growth factor-23 in chronic kidney disease.
    Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
    Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.
    Wöhrle S; Bonny O; Beluch N; Gaulis S; Stamm C; Scheibler M; Müller M; Kinzel B; Thuery A; Brueggen J; Hynes NE; Sellers WR; Hofmann F; Graus-Porta D
    J Bone Miner Res; 2011 Oct; 26(10):2486-97. PubMed ID: 21812026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
    Bai X; Miao D; Li J; Goltzman D; Karaplis AC
    Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice.
    Hesse M; Fröhlich LF; Zeitz U; Lanske B; Erben RG
    Matrix Biol; 2007 Mar; 26(2):75-84. PubMed ID: 17123805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging topics in pediatric bone and mineral disorders 2008.
    McKay CP; Portale A
    Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How fibroblast growth factor 23 works.
    Liu S; Quarles LD
    J Am Soc Nephrol; 2007 Jun; 18(6):1637-47. PubMed ID: 17494882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical practice. Fibroblast growth factor (FGF)23: a new hormone.
    Alon US
    Eur J Pediatr; 2011 May; 170(5):545-54. PubMed ID: 21193927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.
    Prié D; Friedlander G
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1717-22. PubMed ID: 20798257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?
    Stubbs JR; Quarles LD
    Nephrol News Issues; 2009 May; 23(6):33-4, 36-7. PubMed ID: 19534362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 84.